Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma

Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of lung cancer associated with poor prognosis and resistance to conventional chemotherapy. Immune checkpoint inhibitors (ICIs), alone or in combination with chemotherapy, were found to have clinical benefits in PSC in recent studi...

Full description

Bibliographic Details

Published in:	JTO Clinical and Research Reports
Main Authors:	Daisuke Hazama, MD, PhD, Kenji Nakahama, MD, PhD, Hiroaki Kodama, MD, Akito Miyazaki, MD, Koichi Azuma, MD, PhD, Yosuke Kawashima, MD, Yuki Sato, MD, Kentaro Ito, MD, Yoshimasa Shiraishi, MD, Keita Miura, MD, Takayuki Takahama, MD, PhD, Satoshi Oizumi, MD, PhD, Yoshinobu Namba, MD, Satoshi Ikeda, MD, PhD, Hiroshige Yoshioka, MD, PhD, Asuka Tsuya, MD, PhD, Yuichiro Yasuda, MD, PhD, Yoshiki Negi, MD, PhD, Ayako Hara, MD, Michihito Toda, MD, PhD, Motoko Tachihara, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Subjects:	Pulmonary sarcomatoid carcinoma Immune checkpoint inhibitors Real-world data Lung cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S266636432300156X